Page last updated: 2024-09-05

l 365031 and Substance Withdrawal Syndrome

l 365031 has been researched along with Substance Withdrawal Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Coughlan, J; Dourish, CT; Hawley, D; Iversen, SD; Kitchener, SJ; O'Neill, MF	1

Other Studies

1 other study(ies) available for l 365031 and Substance Withdrawal Syndrome

Article	Year
The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. European journal of pharmacology, 1990, Jan-25, Volume: 176, Issue:1 Topics: Analgesia; Animals; Benzodiazepines; Benzodiazepinones; Drug Tolerance; Male; Morphine; Naloxone; Pain; Pain Measurement; Phenylurea Compounds; Rats; Rats, Inbred Strains; Reaction Time; Receptors, Cholecystokinin; Substance Withdrawal Syndrome; Substance-Related Disorders	1990

Article

Year

The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat.

European journal of pharmacology, 1990, Jan-25, Volume: 176, Issue:1

Topics: Analgesia; Animals; Benzodiazepines; Benzodiazepinones; Drug Tolerance; Male; Morphine; Naloxone; Pain; Pain Measurement; Phenylurea Compounds; Rats; Rats, Inbred Strains; Reaction Time; Receptors, Cholecystokinin; Substance Withdrawal Syndrome; Substance-Related Disorders

1990